Premium
Bisphosphonate targeting to specific skeletal sites in mice with whole body vibration
Author(s) -
Papineni Rao V,
Orton Sean,
Ji Tao,
Schmitthenner Hans,
McLaughlin William,
Vizard Douglas,
Pan Jingyi
Publication year - 2010
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.24.1_supplement.583.9
Subject(s) - whole body vibration , bisphosphonate , medicine , osteoporosis , in vivo , drug , biomedical engineering , pharmacology , vibration , biology , physics , microbiology and biotechnology , quantum mechanics
The prospects of a combined targeting, and monitoring of the drug binding to specific skeletal sites by noninvasive means is determined. Site‐selective skeletal targeting of bisphosphonates, if feasible, is ideal to overcome drug‐related side effects. We utilized near‐infrared (NIR) fluorescence imaging to monitor the noninvasive delivery of NIR dye conjugate bisphosphonate, and the role of whole body vibration (WBV) to aid drug targeting. Vibration loading, utilizing whole body vibration (WBV) was performed on twelve mice by subjecting them to vibration frequency of 35 Hz for fifteen min (5–10 times/week) duration. Alendronate was conjugated to near‐infrared tricarbocyanine, cyclic enamine‐functionalized dye, and was injected intravenously after 21‐day exercise regime; the mice were imaged using a commercially available imaging system, KODAK in‐Vivo Multispectral FX system. Besides several specific targeting sites, NIR‐alendronate probe binding to the lumbar L6 vertebrae was explicitly observed, resultant of direct high‐frequency WBV stimulation. The targeted drug binding in response to the vibratory protocol provides hope in the development of whole body vibration (WBV) as a bisphosphonate‐therapeutic aid, and to develop strategies in reducing the drug dosage in osteoporosis treatment.